Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Stoke Therapeutics's Enterprise Value is $1,828.07 Mil.
Stoke Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-177.99 Mil. Therefore, Stoke Therapeutics's EV-to-OCF for today is -10.27.
The historical rank and industry rank for Stoke Therapeutics's EV-to-OCF or its related term are showing as below:
STOK'
s EV-to-OCF Range Over the Past 10 Years
Min: -39.39 Med: -3.41 Max: 43.37
Current: -10.27
During the past 9 years, the highest EV-to-OCF of Stoke Therapeutics was 43.37. The lowest was -39.39. And the median was -3.41.
STOK's EV-to-OCF is ranked better than 69.27% of 1406
companies
in the Biotechnology industry
Industry Median: -3.515
vs STOK: -10.27
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Stoke Therapeutics's PE Ratio (TTM) for today is calculated as:
Stoke Therapeutics's share price for today is $32.84.
Stoke Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.370.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Stoke Therapeutics EV-to-OCF Related Terms
Stoke Therapeutics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Stoke Therapeutics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Stoke Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stoke Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Stoke Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Stoke Therapeutics's EV-to-OCF falls into.
Stoke Therapeutics's current Enterprise Value is $1,828.07 Mil.
Stoke Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-177.99 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stoke Therapeutics (STOK) has a EV-to-OCF of -10.27 as of Aug. 11, 2026. According to the industry distribution chart, Stoke Therapeutics ranks #432 out of 1406 companies in the Biotechnology industry, placing it in the top 30.7%.
Is Stoke Therapeutics' EV-to-OCF too high?
Stoke Therapeutics' current EV-to-OCF is -10.27. Based on the distribution chart, Stoke Therapeutics ranks #432 out of 1406 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Stoke Therapeutics has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Stoke Therapeutics' EV-to-OCF compare to TYRA and SNDX?
According to the Biotechnology industry distribution chart, Stoke Therapeutics ranks #432 out of 1406 companies for EV-to-OCF. This puts Stoke Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Stoke Therapeutics's current EV-to-OCF is -10.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stoke Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Stoke Therapeutics (STOK) is currently considered Significantly Overvalued. The stock's GF Value™ is $9.60, compared to a current price of $32.84 — trading 242.1% above its estimated fair value. The current EV-to-OCF is -10.27. Stoke Therapeutics' overall GF Score™ is 45/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Stoke Therapeutics (STOK), the current EV-to-OCF is -10.27 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stoke Therapeutics (STOK) Overvalued in 2026?
Based on GuruFocus' analysis, Stoke Therapeutics stock appears to be overvalued.
The current stock price of $32.84 is trading 242.1% above its estimated GF Value™ of $9.60.
GuruFocus considers Stoke Therapeutics to be Significantly Overvalued.
Key valuation signals for STOK:
EV-to-OCF: -10.27
GF Value™: $9.60 vs. price of $32.84 (242.1% above fair value)
No single metric tells the full story. See the STOK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
45GF Score
Get the complete analysis for STOK
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STOK has been successfully added to your 
